RXRX Relative Valuation
RXRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RXRX is overvalued; if below, it's undervalued.
Historical Valuation
Recursion Pharmaceuticals Inc (RXRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.45. The fair price of Recursion Pharmaceuticals Inc (RXRX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：4.92
Fair
-3.51
PE
1Y
3Y
5Y
Trailing
Forward
-3.18
EV/EBITDA
Recursion Pharmaceuticals Inc. (RXRX) has a current EV/EBITDA of -3.18. The 5-year average EV/EBITDA is -6.43. The thresholds are as follows: Strongly Undervalued below -21.01, Undervalued between -21.01 and -13.72, Fairly Valued between 0.86 and -13.72, Overvalued between 0.86 and 8.15, and Strongly Overvalued above 8.15. The current Forward EV/EBITDA of -3.18 falls within the Historic Trend Line -Fairly Valued range.
-2.91
EV/EBIT
Recursion Pharmaceuticals Inc. (RXRX) has a current EV/EBIT of -2.91. The 5-year average EV/EBIT is -6.16. The thresholds are as follows: Strongly Undervalued below -19.56, Undervalued between -19.56 and -12.86, Fairly Valued between 0.55 and -12.86, Overvalued between 0.55 and 7.25, and Strongly Overvalued above 7.25. The current Forward EV/EBIT of -2.91 falls within the Historic Trend Line -Fairly Valued range.
30.14
PS
Recursion Pharmaceuticals Inc. (RXRX) has a current PS of 30.14. The 5-year average PS is 85.00. The thresholds are as follows: Strongly Undervalued below -190.09, Undervalued between -190.09 and -52.54, Fairly Valued between 222.54 and -52.54, Overvalued between 222.54 and 360.08, and Strongly Overvalued above 360.08. The current Forward PS of 30.14 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Recursion Pharmaceuticals Inc. (RXRX) has a current P/OCF of 0.00. The 5-year average P/OCF is -9.86. The thresholds are as follows: Strongly Undervalued below -26.00, Undervalued between -26.00 and -17.93, Fairly Valued between -1.80 and -17.93, Overvalued between -1.80 and 6.27, and Strongly Overvalued above 6.27. The current Forward P/OCF of 0.00 falls within the Overvalued range.
-8.91
P/FCF
Recursion Pharmaceuticals Inc. (RXRX) has a current P/FCF of -8.91. The 5-year average P/FCF is -9.51. The thresholds are as follows: Strongly Undervalued below -22.55, Undervalued between -22.55 and -16.03, Fairly Valued between -3.00 and -16.03, Overvalued between -3.00 and 3.52, and Strongly Overvalued above 3.52. The current Forward P/FCF of -8.91 falls within the Historic Trend Line -Fairly Valued range.
Recursion Pharmaceuticals Inc (RXRX) has a current Price-to-Book (P/B) ratio of 2.19. Compared to its 3-year average P/B ratio of 3.57 , the current P/B ratio is approximately -38.61% higher. Relative to its 5-year average P/B ratio of 3.57, the current P/B ratio is about -38.74% higher. Recursion Pharmaceuticals Inc (RXRX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -15.93%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -12.31% , the current FCF yield is about -100.00% lower.
2.31
P/B
Median3y
3.57
Median5y
3.57
-18.43
FCF Yield
Median3y
-15.93
Median5y
-12.31
Competitors Valuation Multiple
The average P/S ratio for RXRX's competitors is 0.00, providing a benchmark for relative valuation. Recursion Pharmaceuticals Inc Corp (RXRX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -80.16%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RXRX decreased by 27.22% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -367.46 to -3.14K.
The secondary factor is the Revenue Growth, contributed -80.16%to the performance.
Overall, the performance of RXRX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Recursion Pharmaceuticals Inc (RXRX) currently overvalued or undervalued?
What is Recursion Pharmaceuticals Inc (RXRX) fair value?
How does RXRX's valuation metrics compare to the industry average?
What is the current P/B ratio for Recursion Pharmaceuticals Inc (RXRX) as of Dec 05 2025?
What is the current FCF Yield for Recursion Pharmaceuticals Inc (RXRX) as of Dec 05 2025?
What is the current Forward P/E ratio for Recursion Pharmaceuticals Inc (RXRX) as of Dec 05 2025?